Faculty of Medicine and Psychology, Neurosciences, Mental Health and Sensory Organ (NESMOS) Department, Sapienza University of Rome, Rome, Italy.
Sant'Andrea University Hospital, Rome, Italy.
Aesthetic Plast Surg. 2023 Jun;47(3):914-926. doi: 10.1007/s00266-022-03138-5. Epub 2022 Nov 14.
Because of poor knowledge of risks and benefits, prophylactic explantation of high BIA-ALCL risk breast implant (BI) is not indicated. Several surgical risks have been associated with BI surgery, with mortality being the most frightening. Primary aim of this study is to assess mortality rate in patients undergoing breast implant surgery for aesthetic or reconstructive indication.
In this retrospective observational cohort study, Breast Implant Surgery Mortality rate (BISM) was calculated as the perioperative mortality rate among 99,690 patients who underwent BI surgery for oncologic and non-oncologic indications. Mean age at first implant placement (A1P), implant lifespan (IL), and women's life expectancy (WLE) were obtained from a literature review and population database.
BISM rate was 0, and mean A1P was 34 years for breast augmentation, and 50 years for breast reconstruction. Regardless of indication, overall mean A1P can be presumed to be 39 years, while mean BIL was estimated as 9 years and WLE as 85 years.
This study first showed that the BISM risk is 0. This information, and the knowledge that BI patients will undergo one or more revisional procedures if not explantation during their lifetime, may help surgeons in the decision-making process of a pre-emptive substitution or explant in patients at high risk of BIA-ALCL. Our recommendation is that patients with existing macrotextured implants do have a relative indication for explantation and total capsulectomy. The final decision should be shared between patient and surgeon following an evaluation of benefits, surgical risks and comorbidities.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
由于对风险和益处的了解不足,预防性摘除高生物免疫激活相关间变大细胞淋巴瘤(BIA-ALCL)风险的乳房植入物(BI)并不被推荐。BI 手术与多种手术风险相关,其中死亡率最为可怕。本研究的主要目的是评估因美容或重建适应证而接受 BI 手术的患者的死亡率。
在这项回顾性观察队列研究中,BI 手术死亡率(BISM)是根据 99690 例因肿瘤和非肿瘤适应证而接受 BI 手术的患者围手术期死亡率计算得出的。首次植入物放置(A1P)时的平均年龄、植入物寿命(IL)和女性预期寿命(WLE)从文献回顾和人口数据库中获得。
BI 手术死亡率为 0,乳房增大的平均 A1P 为 34 岁,乳房重建的平均 A1P 为 50 岁。无论适应证如何,总体平均 A1P 可假定为 39 岁,而平均 BIL 估计为 9 年,WLE 为 85 岁。
本研究首次表明 BISM 风险为 0。这些信息以及 BI 患者在其一生中如果不进行植入物摘除则需要进行一次或多次修正手术的认识,可能有助于外科医生在高 BIA-ALCL 风险患者中进行预防性替代或摘除的决策过程。我们的建议是,对于已经存在粗糙纹理植入物的患者,确实存在摘除和全包膜切除术的相对适应证。最终决定应由患者和外科医生在评估收益、手术风险和合并症后共同做出。
证据水平 IV:本杂志要求作者为每篇文章指定一个证据水平。有关这些循证医学评级的完整描述,请参考目录或在线作者指南 www.springer.com/00266 。